Sana Biotechnology
Sana Biotechnology focuses on creating and delivering engineered cells as medicines, with operations in Seattle, Cambridge, and South San Francisco.
Company Overview
Sana Biotechnology focuses on creating and delivering engineered cells as medicines for patients. The company operates in Seattle, Cambridge, and South San Francisco. It is advancing several innovative drug candidates aimed at treating diseases such as cancer, diabetes, and autoimmune disorders. Sana's mission involves the development of platforms capable of repairing and controlling genes in cells, or replacing any cell in the human body.
Disease Targets
Sana Biotechnology is developing drug candidates to address a range of diseases including cancer, diabetes, and autoimmune disorders. The company's pipeline includes allogeneic CAR T programs targeting CD19+ cancers and autoimmune diseases, and a stem cell-derived pancreatic islet cell program designed for type 1 diabetes. These programs are part of Sana's strategy to innovate treatments with the potential to significantly impact patient health outcomes.
Research and Development Collaborations
Sana Biotechnology is engaged in research and development collaborations with leading academic laboratories and industry partners. These collaborations are fundamental to advancing Sana's innovative drug candidates and platforms. By working with these institutions, Sana leverages cutting-edge science and technology to develop new therapies aimed at treating complex diseases.
Advanced Therapeutic Platforms
Sana Biotechnology is developing several advanced therapeutic platforms. These platforms aim to repair and control genes in cells, or replace any cell in the body. These technologies are at the core of Sana's approach to creating engineered cells that can be used as medicines, addressing a wide range of medical conditions that currently lack effective treatments.